ClinicalTrials.gg
CompletedNCT02005848Updated Oct 11, 2018

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

A Phase 2 interventional study of Alpha-1 Antitrypsin and Placebo in New Onset Type-1 Diabetes, sponsored by Kamada, Ltd.. Completed at 4 sites in Israel. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by Kamada, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
8 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Diabetes Mellitus with a site in Israel — 9 open to participants now, 12 under way, 2 of them phase 3. Diabetes Mellitus · Israel.

Enrollment
99th of 145
70 · median 199
Started
2014
with 6 others
Phase 2
16 of 189
none open now
Registered
112th of 189
by date

Among the 189 studies in Diabetes Mellitus with a site in Israel, this one is the 99th largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2014, is one of 16 in phase 2, and was the 112th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

9 of the 189 studies in Diabetes Mellitus with a site in Israel are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 8 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Diabetes Mellitus with a site in Israel, or all of them as a file.
02

Study summary

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes.

The study objectives are:

  • To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes
  • To assess the safety and tolerability of intravenous AAT in new onset Type 1 Diabetes pediatric and young adult population.
03

Conditions studied

  • New Onset Type-1 Diabetes

Browse trials for

Keywords

  • Type-1 Diabetes
  • T1D
  • Diabetes Mellitus
04

Who can participate

Ages eligible
8 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Subject (or parent/guardian) willing and able to sign an
  • Age 8-25 (inclusive) years
  • Recently diagnosed with T1DM
  • Basal C-peptide ≥ 0.2 pmol/mL
  • Positive for at least one diabetes-related autoantibody
  • Ability and consent to comply with completion of patient diary
  • No significant abnormalities in serum hematology, serum chemistry
  • No significant abnormalities in urinalysis
  • No significant abnormalities in
  • For women of child bearing potential, non-pregnant, non-lactating female patients

Main Exclusion Criteria:

  • IgA deficient subjects
  • Subjects who have received an active/ within 4 weeks of the screening date
  • Subjects who have received treatment with medication within 2 months prior to screening or any or cytostatic agent within 6 months prior to screening
  • Individuals with a history of severe immediate reactions, including anaphylaxis, to plasma products
  • intercurrent illnesses
  • Pregnant or lactating women
  • Current use of any medication known to influence glucose tolerance
  • Current or prior (within the last 60 days prior to screening visit) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Alpha1 Antitrypsin (Glassia)

    60 mg/kg body weight

    Biological: Alpha-1 Antitrypsin

  • Experimental
    Alpha-1 Antitrypsin (Glassia)

    120 mg/kg body weight

    Biological: Alpha-1 Antitrypsin

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • Also known as: Humman Alpha-1 Antitrypsin, Alpha-1 Proteinase Inhibitor, API, AAT

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Beta cell function

    Beta cell function (measured by C peptide)

    Time frame: 12 months from baseline

Secondary outcomes

  1. Glycemic control

    Glycemic control expressed in HbA1c level

    Time frame: 12 months from baseline

  2. Beta cell function

    Time frame: 12 months from baseline

  3. Insulin dose

    Time frame: 12 months from baseline

  4. Hypoglycemic episodes

    Time frame: 12 months from baseline

  5. Safety parameters

    Adverse events, vital signs, physical examination

    Time frame: 12 months from baseline

07

Study locations

4 sites
  • Soroka Medical Center
    Beer Sheva, Israel
  • Rambam Medical Center
    Haifa, Israel
  • Schneider Children's Medical Center
    Pethach Tikva, Israel
  • Assaf Harofe Medical Center
    Zerifin, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2013
First posted
Dec 9, 2013
Start
Apr 2014
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
Oct 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02005848
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Apr 2014
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Oct 11, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion